Request that the FDA grant public disclosure of the clinical pharmacology / bioavailability data supporting the approval of Tylenol with Naproxen (acetaminophen 325 mg / naproxen sodium 110 mg fixed-dose combination tablets), approved July 24, 2026, Kenvue Brands LLC
🏛 Food and Drug Administration (FDA)FDA-2026-P-8331
Documents
2
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Jul 30, 2026No comment period